Inhibition of Glutaminyl Cyclases alleviates CCL2-mediated inflammation of non-alcoholic fatty liver disease in mice

International Journal of Experimental Pathology

Volumn 94, Issue 3, 2013, Pages 217-225

  Cynis, Holger ^a,b   Kehlen, Astrid ^a   Haegele, Monique ^a   Hoffmann, Torsten ^a   Heiser, Ulrich ^a   Fujii, Masato ^c   Shibazaki, Yuichiro ^c   Yoneyama, Hiroyuki ^c   Schilling, Stephan ^a   Demuth, Hans Ulrich ^a  

^a PROBIODRUG AG   (Germany)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Stelic Institute and Co   (Japan)

Author keywords

Chemokine; Glutaminyl cyclases; NAFLD; Posttranslational modification; Pyroglutamate

Indexed keywords

ALANINE AMINOTRANSFERASE; COLLAGEN; GLUTAMINYL CYCLASE; MACROPHAGE DERIVED CHEMOKINE; MONOCYTE CHEMOTACTIC PROTEIN 1; PYROGLUTAMIC ACID; TELMISARTAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATALYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HISTOPATHOLOGY; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LIVER CELL; LIVER FIBROSIS; LIVER PARENCHYMA; MACROPHAGE; MONOCYTE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; SIGNAL TRANSDUCTION; UPREGULATION;

AMINOACYLTRANSFERASES; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BENZIMIDAZOLES; BENZOATES; CELL LINE, TUMOR; CHEMOKINE CCL2; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FATTY LIVER; HEPATITIS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LEUKEMIA, MONOCYTIC, ACUTE; MACROPHAGES; MICE; MICE, INBRED C57BL; MONOCYTES;

EID: 84877926004     PISSN: 09599673     EISSN: 13652613     Source Type: Journal    
DOI: 10.1111/iep.12020     Document Type: Article

References (37)

1. Abraham G.N. & Podell D.N. (1981) Pyroglutamic acid Non-metabolic formation, function in proteins and peptides, and characteristics of the enzymes effecting its removal. Mol. Cell. Biochem. 38. Spec No(Pt 1), 181-190.
2. Anstee Q.M. & Goldin R.D. (2006) Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int. J. Exp. Pathol. 87, 1-16.
3. Baeck C., Wehr A., Karlmark K.R. et al. (2012) Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury. Gut 61, 416-426.
4. Bataller R. & Brenner D.A. (2005) Liver fibrosis. J. Clin. Invest. 115, 209-218.
5. Braunersreuther V., Viviani G.L., Mach F., Montecucco F. (2012) Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J. Gastroenterol. 18, 727-735.
6. Bugianesi E., Vanni E., Marchesini G. (2007) NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes. Curr. Diab. Rep. 7, 175-180.
7. Cai D., Yuan M., Frantz D.F. et al. (2005) Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat. Med. 11, 183-190.
8. Clark J.M. (2006) The epidemiology of nonalcoholic fatty liver disease in adults. J. Clin. Gastroenterol. 40(Suppl. 1), S5-S10.
9. Cynis H., Hoffmann T., Friedrich D. et al. (2011) The isoenzyme of glutaminyl cyclase is an important regulator of monocyte infiltration under inflammatory conditions. EMBO Mol. Med. 3, 545-558.
10. Dowman J.K., Tomlinson J.W., Newsome P.N. (2010) Pathogenesis of non-alcoholic fatty liver disease. QJM 103, 71-83.
11. Duvnjak M., Lerotic I., Barsic N., Tomasic V., Virovic J.L., Velagic V. (2007) Pathogenesis and management issues for non-alcoholic fatty liver disease World J. Gastroenterol. 13, 4539-4550.
12. Fischer W.H. & Spiess J. (1987) Identification of a mammalian glutaminyl cyclase converting glutaminyl into pyroglutamyl peptides. Proc. Natl Acad. Sci. USA 84, 3628-3632.
13. Folch J., Lees M., Sloane Stanley G.H. (1957) A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 226, 497-509.
14. Fujita K., Yoneda M., Wada K. et al. (2007) Telmisartan, an angiotensin II type 1 receptor blocker, controls progress of nonalcoholic steatohepatitis in rats. Dig. Dis. Sci. 52, 3455-3464.
15. Georgescu E.F., Ionescu R., Niculescu M., Mogoanta L., Vancica L. (2009) Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J. Gastroenterol. 15, 942-954.
16. Haukeland J.W., Damas J.K., Konopski Z. et al. (2006) Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J. Hepatol. 44, 1167-1174.
17. Hui J.M., Hodge A., Farrell G.C., Kench J.G., Kriketos A., George J. (2004) Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 40, 46-54.
18. Kanda H., Tateya S., Tamori Y. et al. (2006) MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J. Clin. Invest. 116, 1494-1505.
19. Karlmark K.R., Weiskirchen R., Zimmermann H.W. et al. (2009) Hepatic recruitment of the inflammatory Gr1 + monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology 50, 261-274.
20. Kawai D., Takaki A., Nakatsuka A. et al. (2012) Hydrogen-rich water prevents progression of non-alcoholic steatohepatitis and accompanying hepatocarcinogenesis in mice. Hepatology 56, 912-921.
21. Kleiner D.E., Brunt E.M., van Natta M. et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313-1321.
22. Loberg R.D., Ying C., Craig M. et al. (2007) Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. Cancer Res. 67, 9417-9424.
23. Miura K., Yang L., van Rooijen N., Ohnishi H., Seki E. (2012) Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. Am. J. Physiol. Gastrointest. Liver Physiol. 302, G1310-G1321.
24. Morty R.E., Bulau P., Pelle R., Wilk S., Abe K. (2006) Pyroglutamyl peptidase type I from Trypanosoma brucei: a new virulence factor from African trypanosomes that de-blocks regulatory peptides in the plasma of infected hosts. Biochem. J. 394, 635-645.
25. Musso G., Gambino R., Cassader M., Pagano G. (2010) A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 52, 79-104.
26. Preiss D. & Sattar N. (2008) Non-alcoholic fatty liver disease: An overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin. Sci. (Lond) 115, 141-150.
27. Qian B.Z., Li J., Zhang H. et al. (2011) CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 475, 222-225.
28. Sanyal A.J., Chalasani N., Kowdley K.V. et al. (2010a) Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Eng. J. Med. 362, 1675-1685.
29. Sanyal A.J., Yoon S.K., Lencioni R. (2010b) The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist. 15(Suppl 4), 14-22.
30. Schilling S., Kohlmann S., Baeuscher C. et al. (2011) Glutaminyl cyclase (QC) knockout mice show mild hypothyreodism but absence of hypogonadism: implications for enzyme function and drug development. J. Biol. Chem. 286, 12790-12801.
31. Schuppan D., Gorrell M.D., Klein T., Mark M., Afdhal, N.H. (2010) The challenge of developing novel pharmacological therapies for non-alcoholic steatohepatitis. Liver Int. 30, 795-808.
32. Uguccioni M., D'Apuzzo M., Loetscher M., Dewald B., Baggiolini M. (1995) Actions of the chemotactic cytokines MCP-1, MCP-2, MCP-3, RANTES, MIP-1 alpha and MIP-1 beta on human monocytes. Eur. J. Immunol. 25, 64-68.
33. Uguccioni M., Loetscher P., Forssmann U. et al. (1996) Monocyte chemotactic protein 4 (MCP-4), a novel structural and functional analogue of MCP-3 and eotaxin. J. Exp. Med. 183, 2379-2384.
34. Yoneyama H., Harada A., Imai T. et al. (1998) Pivotal role of TARC, a CC chemokine, in bacteria-induced fulminant hepatic failure in mice. J. Clin. Invest. 102, 1933-1941.
35. Yoneyama H., Matsuno K., Zhang Y. et al. (2001) Regulation by chemokines of circulating dendritic cell precursors, and the formation of portal tract-associated lymphoid tissue, in a granulomatous liver disease. J. Exp. Med. 193, 35-49.
36. Yuan M., Konstantopoulos N., Lee J. et al. (2001) Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 293, 1673-1677.
37. Zimmermann H.W. & Tacke F. (2011) Modification of chemokine pathways and immune cell infiltration as a novel therapeutic approach in liver inflammation and fibrosis. Inflamm. Allergy Drug Targets 10, 509-536.